Psychedelics – News and Features

A recent study challenges the effectiveness of microdosing LSD for treating ADHD. Despite self-reported improvements, the clinical trial found no significant difference between low-dose LSD and placebo in reducing ADHD symptoms.

A single dose of psilocin can induce changes in human nerve cells, providing researchers with a better understanding of the mechanisms behind psilocin's effects.

A Monash-led study evaluated MDMA-assisted psychotherapy (MDMA-AP) for PTSD, finding symptom improvement but low-certainty evidence. The findings will inform Australia’s first clinical guidelines on MDMA-AP.

Cold Spring Harbor Laboratory researchers confirm the existence of GluN1-2B-2D, a brain receptor targeted by ketamine. Using cryo-EM, they visualize how ketamine binds to the receptor, controlling its ion channel activity.

New research has made a breakthrough in understanding how our cells manage to stay healthy by recycling important fat molecules.

A new study finds that oral ketamine significantly reduces PTSD symptoms, with 73% of participants seeing a 50% reduction in symptoms. The treatment, taken as a liquid drink, was well-tolerated and had fewer side effects than intravenous ketamine.

The “magic mushroom” psychedelic compound – psilocybin – may help to improve mental health symptoms faced by cancer patients when used alongside psychotherapy.

University of Arizona researchers uncovered how levodopa-induced dyskinesia disrupts motor cortex function in Parkinson’s patients. Exploring ketamine as a treatment, they found it promotes neuroplasticity and restores control over movement.

Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care.

Spinal cord stimulation is often a last resort for those with intractable chronic pain. A new 10-minute brain scan gives doctors a much-needed biomarker to discuss with patients considering spinal cord stimulation.